At a glance
ClinicalIndex Comparison RecordN/ACompleted· 813 enrolled
Drug / intervention
Palbociclib + an aromatase inhibitor +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Real-world Treatment Patterns and Effectiveness of Palbociclib in Combination With an Aromatase Inhibitor as Initial Endocrine Based Therapy in Metastatic/Advanced Breast Cancer
In Brief
An observational study evaluating Palbociclib + an aromatase inhibitor, Palbociclib + Letrozole, and 1 other intervention for Metastatic Breast Cancer. Completed, enrolled 813 participants across 1 site.
Detailed Summary
A retrospective observational analysis of de-identified Flatiron Health Analytic Database to describe patient characteristics, treatment patterns and effectiveness of Palbociclib + AI as first-line therapy in HR+/HER2- metastatic breast cancer (MBC) in the US clinical practices.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Breast Cancer
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20192020202120222023202420252026
Enrollment StartJan 2019
Primary CompletionSep 2019
First PostedNov 2019
TodayJul 2026
First PostedNov 25, 2019
Enrollment StartJan 25, 2019
Primary CompletionSep 27, 2019
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 6.6 years ago
Interventions
Palbociclib + an aromatase inhibitordrug
Palbociclib + an aromatase inhibitor therapy
Palbociclib + Letrozoledrug
Palbociclib + Letrozole therapy
Letrozoledrug
Letrozole monotherapy